Patents by Inventor Lloyd P. Aiello

Lloyd P. Aiello has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating vascular permeability
    Patent number: 8841259
    Abstract: The present invention provides methods and composition for the treatment and diagnosis of disorders associated with excessive vascular permeability and edema.
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: September 23, 2014
    Assignee: Joslin Diabetes Center
    Inventors: Edward P. Feener, Lloyd P. Aiello
  • Methods for treatment of kallikrein-related disorders
    Patent number: 8658685
    Abstract: We have identified classes of kallikrein inhibitors as compounds that are useful in the reduction of vascular permeability (e.g., retinal vascular permeability and cerebral vascular permeability) and astrocyte activation. Diseases and conditions associated with increased vascular permeability include diabetic retinopathy, hemorrhagic stroke, and macular edema. Diseases and conditions associated with astrocyte activation include Alzheimer's disease, multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, stroke, epilepsy, and brain trauma.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: February 25, 2014
    Assignees: Activesite Pharmaceuticals, Inc., Joslin Diabetes Center
    Inventors: Lloyd P. Aiello, Tamie Jo Chilcote, Sukanto Sinha, Edward P. Feener
  • METHODS FOR TREATMENT OF KALLIKREIN-RELATED DISORDERS
    Publication number: 20110065757
    Abstract: We have identified classes of kallikrein inhibitors as compounds that are useful in the reduction of vascular permeability (e.g., retinal vascular permeability and cerebral vascular permeability) and astrocyte activation. Diseases and conditions associated with increased vascular permeability include diabetic retinopathy, hemorrhagic stroke, and macular edema. Diseases and conditions associated with astrocyte activation include Alzheimer's disease, multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, stroke, epilepsy, and brain trauma.
    Type: Application
    Filed: January 30, 2009
    Publication date: March 17, 2011
    Applicants: JOSKIN DIABETES CENTER, ACTIVESITE PHARMACEUTICALS, INC.
    Inventors: Lloyd P. Aiello, Tamie Jo Chilcote, Sukanto Sinha, Edward P. Feener
  • METHODS OF DIAGNOSING, TREATING, AND PREVENTING INCREASED VASCULAR PERMEABILITY
    Publication number: 20100119512
    Abstract: The present invention provides methods for the treatment and diagnosis of disorders associated with excessive vascular permeability and edema.
    Type: Application
    Filed: January 25, 2008
    Publication date: May 13, 2010
    Applicant: Joslin Diabetes Center
    Inventors: Edward P. Feener, Lloyd P. Aiello
  • COMPOSITIONS AND METHODS FOR TREATING DIABETIC EYE DISEASE
    Publication number: 20090069231
    Abstract: The present invention provides methods and composition for the treatment and diagnosis of disorders associated with excessive retinal vascularisation and vascular permeability, e.g., diabetic retinopathy and diabetic macular edema.
    Type: Application
    Filed: February 19, 2008
    Publication date: March 12, 2009
    Inventors: Lloyd P. Aiello, Edward P. Feener
  • Compositions and Methods for Treating Vascular Permeability
    Publication number: 20080280811
    Abstract: The present invention provides methods and composition for the treatment and diagnosis of disorders associated with excessive vascular permeability and edema.
    Type: Application
    Filed: February 16, 2006
    Publication date: November 13, 2008
    Inventors: Edward P. Feener, Lloyd P. Aiello
  • Methods of modulating symptoms of hypertension
    Publication number: 20020091082
    Abstract: The invention features methods of treating hypertension and related disorders and conditions, e.g., diabetic retinopathy, by inhibiting VEGF-KDR signaling pathway components, e.g., PKC-zeta and/or PI3 kinase 1.
    Type: Application
    Filed: September 13, 2001
    Publication date: July 11, 2002
    Inventor: Lloyd P. Aiello
  • Therapeutic treatment for VEGF related diseases
    Patent number: 6284751
    Abstract: A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with neoplasia, and VEGF stimulated capillary permeability, such as associated with pulmonary edema are disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-[N,N′-1,1′-((2″-ethoxy)-3′″(O)-4′″-(N,N-dimethylamino)-butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dionehydrochloridesalt.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: September 4, 2001
    Assignee: Eli Lilly and Company
    Inventors: Lloyd P. Aiello, Michael R. Jirousek, George L. King, Louis Vignati, Douglas Kirk Ways
  • Therapeutic treatment for VEGF related ocular diseases
    Patent number: 6114320
    Abstract: A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with macular degeneration, and VEGF stimulated capillary permeability, such as associated with macular edema are disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indoly 1)]-1(H)-pyrrole-2,5-dionehydrochloridesalt.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: September 5, 2000
    Assignees: Eli Lilly and Company, Joslin Diabetes Center
    Inventors: Lloyd P. Aiello, Michael R. Jirousek, George L. King, Louis Vignati, Douglas Kirk Ways